Profile data is unavailable for this security.
About the company
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for patients with autoimmune diseases. The Company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.
- Revenue in USD (TTM)15.00m
- Net income in USD-189.90m
- Incorporated2023
- Employees130.00
- LocationZenas Biopharma Inc1000 Winter St, Suite 1200WALTHAM 02451United StatesUSA
- Phone+1 (857) 271-2954
- Fax+1 (302) 655-5049
- Websitehttps://zenasbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AtaiBeckley Inc | 3.02m | -154.19m | 1.30bn | 54.00 | -- | 5.37 | -- | 428.91 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.31bn | 147.00 | 71.52 | 4.50 | 44.63 | 7.20 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Azenta Inc | 594.95m | 28.69m | 1.32bn | 3.00k | 45.77 | 0.768 | 15.43 | 2.22 | 0.6252 | -1.26 | 12.98 | 37.26 | 0.2891 | 4.03 | 4.00 | 198,317.70 | 1.39 | -0.3901 | 1.57 | -0.4328 | 44.59 | 45.32 | 4.82 | -1.73 | 2.61 | -- | 0.00 | -- | 3.55 | 8.85 | 200.38 | -- | -3.24 | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.33bn | 69.00 | -- | 2.60 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.33bn | 26.00 | -- | 7.03 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| Kodiak Sciences Inc | 0.00 | -217.34m | 1.35bn | 123.00 | -- | 49.37 | -- | -- | -4.12 | -4.12 | 0.00 | 0.447 | 0.00 | -- | -- | 0.00 | -73.58 | -33.79 | -82.91 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| Intellia Therapeutics Inc | 57.53m | -445.81m | 1.37bn | 403.00 | -- | 1.84 | -- | 23.90 | -4.27 | -4.27 | 0.5488 | 6.46 | 0.0548 | -- | 5.78 | 142,749.40 | -42.49 | -33.78 | -46.95 | -37.16 | -- | -- | -774.94 | -790.71 | -- | -- | 0.00 | -- | 59.55 | 6.07 | -7.86 | -- | -3.19 | -- |
| Novavax Inc | 1.06bn | 341.75m | 1.41bn | 952.00 | 4.84 | -- | 3.75 | 1.33 | 1.80 | 1.80 | 6.29 | -0.9643 | 0.7362 | 7.87 | 16.49 | 1,118,331.00 | 23.63 | -39.12 | 53.33 | -248.97 | 91.82 | -- | 32.10 | -67.41 | 2.24 | 17.15 | 2.66 | -- | -30.65 | 105.39 | 65.60 | -- | 47.71 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.42bn | 130.00 | -- | 5.67 | -- | 94.48 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Alvotech SA | 573.35m | 69.50m | 1.45bn | 1.01k | 22.17 | -- | 13.76 | 2.52 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.45bn | 61.00 | -- | 16.48 | -- | 23.18 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| AnaptysBio Inc | 169.47m | -84.63m | 1.47bn | 136.00 | -- | -- | -- | 8.67 | -2.82 | -2.82 | 5.70 | -1.07 | 0.4004 | -- | 3.86 | 1,246,081.00 | -19.99 | -19.96 | -22.14 | -21.08 | -- | -- | -49.94 | -200.59 | -- | -- | 1.10 | -- | 432.03 | 62.73 | 11.24 | -- | -14.96 | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.49bn | 60.00 | -- | 5.32 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Biohaven Ltd | 0.00 | -780.11m | 1.51bn | 256.00 | -- | -- | -- | -- | -7.60 | -7.60 | 0.00 | -0.1622 | 0.00 | -- | -- | 0.00 | -169.65 | -- | -238.45 | -- | -- | -- | -- | -- | -- | -- | 1.07 | -- | -- | -- | -107.37 | -- | -- | -- |
| Celldex Therapeutics Inc | 2.60m | -224.53m | 1.53bn | 186.00 | -- | 2.55 | -- | 587.82 | -3.38 | -3.38 | 0.0392 | 9.01 | 0.0035 | -- | 5.52 | 13,978.49 | -30.51 | -27.70 | -32.24 | -29.29 | -- | -- | -8,635.85 | -1,912.91 | -- | -- | 0.00 | -- | 1.99 | 14.46 | -11.62 | -- | 21.29 | -- |
Data as of Feb 13 2026. Currency figures normalised to Zenas Biopharma Inc's reporting currency: US Dollar USD
28.74%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 4.16m | 7.75% |
| Federated Global Investment Management Corp.as of 31 Dec 2025 | 2.72m | 5.06% |
| Fairmount Funds Management LLCas of 07 Oct 2025 | 2.21m | 4.12% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.58m | 2.94% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.25m | 2.33% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 855.52k | 1.59% |
| ArrowMark Colorado Holdings LLCas of 30 Sep 2025 | 824.67k | 1.54% |
| FIAM LLCas of 30 Sep 2025 | 659.31k | 1.23% |
| Geode Capital Management LLCas of 31 Dec 2025 | 588.39k | 1.10% |
| Rock Springs Capital Management LPas of 30 Sep 2025 | 580.68k | 1.08% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
